

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|---|----|---|------------------------|----------------|
| Substitute for form 1449/PTO | | | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/778,002 |
| Sheet | 1 | of | 3 | Filing Date | 02/11/2004 |
| | | | | First Named Inventor | Birgit OPPMANN |
| | | | | Art Unit | 1640- 1649 |
| | | | | Examiner Name | Hayes |
| | | | | Attorney Docket Number | DX0935KB |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------|---|------------------|---|--|
| Examiner Initials* | Cite No.* | DOCUMENT NUMBER | Publication Date | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear |
| | | Number-Kind Code* ² (if known) | MM-DD-YYYY | | |
| RH | AA | 5,457,038A | 10-10-1995 | TRINCHIERI, et al. | |
| RH AB | | 5,741,772A | 04-21-1998 | CHANG | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|-----------|---|------------------|---|--|
| Examiner Initials* | Cite No.* | Foreign Patent Document | Publication Date | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear |
| | | Country Code* Number-Kind Code* ² (if known) | MM-DD-YYYY | | T ⁴ |
| RH | AC | WO 98/33922A1 | 08-06-1998 | CHANG, et al. | |
| | AD | WO 99/00415A1 | 01-07-1999 | SHI, et al. | |
| | AE | WO 98/11225A2 | 03-19-1998 | HILTON, et al. | |
| | AF | WO 98/31811A1 | 07-23-1998 | DONALDSON, et al. | |
| | AG | WO 98/49307A1 | 11-05-1998 | LOK, et al. | |
| | AH | WO 95/11303A1 | 4-27-1995 | STAHL, et al. | |
| | AI | WO 99/20755A2 | 4-29-1999 | ELSON, et al. | |
| | AJ | WO 99/28462A2 | 6-10-1999 | WOOD, et al. | |
| | AK | WO 99/35264A1 | 7-15-1999 | COSMAN, et al. | |
| | AL | WO 99/40195A1 | 8-12-1999 | MATTSON, et al. | |
| V | AM | EP 0759466A2 | 02-26-1997 | GUBLER, et al. | |

| | | | |
|--------------------|----------------|-----------------|------------|
| Examiner Signature | /Robert Hayes/ | Date Considered | 03/27/2007 |
|--------------------|----------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kirks Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.67 and 1.68. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|----------------|
| Substitute for form 1440/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/778,002 |
| Sheet | 2 | of | 3 | Filing Date | 02/11/2004 |
| | | | | First Named Inventor | Birgit OPPMANN |
| | | | | Art Unit | 1646 1649 |
| | | | | Examiner Name | |
| | | | | Attorney Docket Number | DX0935KB |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|---|-------------------------------|
| no | AN | BECHIARA, et al., "Mice lacking the CNTF receptor, unlike mice lacking CNTF, exhibit profound motor neuron deficitis at birth." Cell, 83(2):313-322 (October 20, 1995). | |
| copies in parent | AO | ELSON, et al., "Homo sapiens cytokine-like factor-1 precursor (CLF-1) mRNA, complete cds." GenBank, Accession No. AF059293 (August 2, 1998). | |
| | AP | ELSON, et al., "Cytokine-Like factor-1, a novel soluble protein, shares homology with member of the cytokine type I receptor family." J. Immunol. 161(3):1371-1379 (August 1, 1998). | |
| | AQ | FISCHER, et al., "A biopactive designer cytokine for human hematopoietic progenitor cell expansion." Nat. Biotechnol., 15(2):142-145 (February 1997). | |
| | AR | GATELY, et al., "The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses" Annu. Rev. Immunol., 16:495-521 (1998). | |
| | AS | GOUGH, "Murine mRNA for leukaemia inhibitory factor (LIF)." GenBank, Accession Number X06381 (July 13, 1995). | |
| | AT | HABECKER, et al., "A sweat gland-derived differentiation activity acts through known cytokine signaling pathways" J. Biol. Chem., 272(48):30421-30428 (November 28, 1997). | |
| | AU | MCDONALD, "Human CNTF gene for ciliary neurotrophic factor," GenBank, Accession No. X60542 (August 16, 1991). | |
| | AV | PENNICA, et al., "Mus musculus cardiotrophin-1 mRNA, complete cds." GenBank, Accession No. U18366 (March 15, 1995). | |
| | AW | PENNICA, et al., "Human cardiotrophin-1 (CTF1) mRNA, complete cds." GenBank, Accession No. U43030 (January 9, 1996). | |
| RH | AX | PETERS, et al., "In vivo and in vitro activities of the gp130-stimulating designer cytokine hyper-IL-6." J. Immunol. 161(7):3575-3581 (October 1, 1998). | |
| RH | AY | RAKEMANN, et al., "The designer cytokine hyper-interleukin-6 is a potent activator of STAT3-dependent gene transcription in vivo and in vitro," J. Biol. Chem. 274(3):1257-1266 (January 1999). | |
| | AZ | SAOTOME, et al., "Mus musculus zinc finger protein (Pzf) mRNA, partial cds, and ciliary neurotrophic factor (Cnfr) mRNA, complete cds." GenBank, Accession No. U06342 (November 20, 1995). | |
| Examiner Signature | /Robert Hayes/ | | Date Considered 03/27/2007 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 806. Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.68. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/088 (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

| | | | | | |
|--|---|----|---|-------------------|----------|
| Substitute for form 1449/PTO | | | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | | |
| (Use as many sheets as necessary) | | | | | |
| Sheet | 3 | of | 3 | Examiner Name | DX0935KB |

| | | | |
|--------------------|----------|---|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ^a |
| RH | BA | SENALDI, et al., "Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family," Proc. Natl. Acad. Sci. USA 96(20):11458-11463 (September 28, 1999). | |
| | BB | SHELTON, "Are there more members of the CNTF-GPA family?", Persp. Devol. Neurobiol., 4(1):104-107 (1996). | |
| RH | BC | SHI, et al. "Computational EST database analysis identifies a novel member of the neurotrophic cytokine family," Biochim. Biophys. Res. Commun., 262(1):132-138 (August 19, 1999). | |
| no | BD | STAHL, et al., "Human leukemia Inhibitory factor (LIF) gene, complete cds," GenBank Accession No. M63420 (October 31, 1994). | |
| copies in | BE | TRINCHIERI, "Proinflammatory and immunoregulatory functions of interleukin-12," Intern. Rev. Immunol. 16(3-4):365-396 (1998). | |
| parent | BF | WARE, et al., "Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death," Development 121(5):1283-1299 (May 1995). | |
| | BG | Database DGENE, Last updated 13-JUN-1999, Result from sequence search using SEQ ID NO:2, as the query and citing Accession Numbers: 99P-W94466, 98P-W56141, 98P-W29715, 98P-W56142, 98P-W28716, 97P-W29237, 96P-R88204, 95P-R83965; Derwent Information Ltd., London. | |
| | BH | Database DGENE, Last updated 13-JUN-1999, Result from sequence search using SEQ ID NO:12 as the query and citing Accession Numbers: 98P-W59805, 98P-W55012, 98P-W55011, 98P-W69804, 98P-W55014, 98P-W56015, 98P-W55016, 92P-R26334, 97P-W17859, 98P-R94576, 92P-R24273, 92P-R22228, 91P-R10795; Derwent Information Ltd., London. | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|----------------|-----------------|------------|
| Examiner Signature | /Robert Hayes/ | Date Considered | 03/27/2007 |
|--------------------|----------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^aApplicant's unique citation designation number (optional). ^bApplicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-8199 (1-800-786-8199) and select option 2.